EP4249505A4 - Long-acting glucagon derivative - Google Patents
Long-acting glucagon derivative Download PDFInfo
- Publication number
- EP4249505A4 EP4249505A4 EP20966375.6A EP20966375A EP4249505A4 EP 4249505 A4 EP4249505 A4 EP 4249505A4 EP 20966375 A EP20966375 A EP 20966375A EP 4249505 A4 EP4249505 A4 EP 4249505A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- long
- glucagon derivative
- acting glucagon
- acting
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/138597 WO2022133797A1 (en) | 2020-12-23 | 2020-12-23 | Long-acting glucagon derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4249505A1 EP4249505A1 (en) | 2023-09-27 |
| EP4249505A4 true EP4249505A4 (en) | 2024-08-21 |
Family
ID=82158584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20966375.6A Pending EP4249505A4 (en) | 2020-12-23 | 2020-12-23 | Long-acting glucagon derivative |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240059752A1 (en) |
| EP (1) | EP4249505A4 (en) |
| JP (1) | JP7573760B2 (en) |
| KR (1) | KR20230126712A (en) |
| CN (2) | CN118184764A (en) |
| AU (1) | AU2020483085B2 (en) |
| CA (1) | CA3205610A1 (en) |
| WO (1) | WO2022133797A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116710462A (en) | 2021-01-20 | 2023-09-05 | 维京治疗公司 | Compositions and methods for treating metabolic disorders and liver diseases |
| CN118265720A (en) | 2021-09-15 | 2024-06-28 | 维京治疗公司 | Compositions and methods for treating metabolic disorders and liver diseases |
| CN117586374B (en) * | 2023-10-07 | 2024-11-29 | 深圳湾实验室 | GLP-1R/GIPR/GCGR triple agonist analogs and their uses |
| CN119285747A (en) * | 2024-10-14 | 2025-01-10 | 晨伫(杭州)生物科技有限责任公司 | A GLP-1 derivative and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013192129A1 (en) * | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| WO2019101036A1 (en) * | 2017-11-24 | 2019-05-31 | 浙江道尔生物科技有限公司 | Multiple-active protein for treating metabolic diseases |
| WO2020228360A1 (en) * | 2019-05-16 | 2020-11-19 | 浙江道尔生物科技有限公司 | Fusion protein for treatment of metabolic disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | GLUCAGON / GLP-I RECEPTOR CO-AGONISTS |
| MX2013006304A (en) * | 2010-12-22 | 2013-07-02 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGS THAT DISPLAY ACTIVITY OF THE GIP RECEIVER. |
| US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| US10100097B2 (en) * | 2012-05-03 | 2018-10-16 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| CA2877127A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting gip receptor activity |
| KR102310392B1 (en) * | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | Glucagon-glp-1-gip triple agonist compounds |
| CN115304666B (en) * | 2017-11-24 | 2025-09-19 | 浙江道尔生物科技有限公司 | Glucagon analogues for the treatment of metabolic disorders |
| CN111349155B (en) * | 2018-12-24 | 2022-04-05 | 浙江和泽医药科技股份有限公司 | Glucagon analogue and preparation method and application thereof |
| US20220127323A1 (en) * | 2019-01-07 | 2022-04-28 | Vitalixir (Beijing) Co., Ltd | Novel polypeptide and therapeutic uses thereof |
-
2020
- 2020-12-23 CN CN202410362929.2A patent/CN118184764A/en active Pending
- 2020-12-23 KR KR1020237024096A patent/KR20230126712A/en active Pending
- 2020-12-23 EP EP20966375.6A patent/EP4249505A4/en active Pending
- 2020-12-23 WO PCT/CN2020/138597 patent/WO2022133797A1/en not_active Ceased
- 2020-12-23 CA CA3205610A patent/CA3205610A1/en active Pending
- 2020-12-23 JP JP2023558918A patent/JP7573760B2/en active Active
- 2020-12-23 AU AU2020483085A patent/AU2020483085B2/en active Active
- 2020-12-23 US US18/266,597 patent/US20240059752A1/en active Pending
- 2020-12-23 CN CN202080060387.3A patent/CN114981294B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013192129A1 (en) * | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| WO2019101036A1 (en) * | 2017-11-24 | 2019-05-31 | 浙江道尔生物科技有限公司 | Multiple-active protein for treating metabolic diseases |
| WO2020228360A1 (en) * | 2019-05-16 | 2020-11-19 | 浙江道尔生物科技有限公司 | Fusion protein for treatment of metabolic disease |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2022133797A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022133797A1 (en) | 2022-06-30 |
| EP4249505A1 (en) | 2023-09-27 |
| CN114981294A (en) | 2022-08-30 |
| AU2020483085A1 (en) | 2023-07-06 |
| CN114981294B (en) | 2024-04-26 |
| CA3205610A1 (en) | 2022-06-30 |
| JP2023552500A (en) | 2023-12-15 |
| CN118184764A (en) | 2024-06-14 |
| JP7573760B2 (en) | 2024-10-25 |
| US20240059752A1 (en) | 2024-02-22 |
| AU2020483085B2 (en) | 2024-03-07 |
| AU2020483085A9 (en) | 2025-04-10 |
| KR20230126712A (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4249505A4 (en) | Long-acting glucagon derivative | |
| EP4086277A4 (en) | Long-acting glp-1 compound | |
| EP4086279A4 (en) | Insulin derivative | |
| EP3741756A4 (en) | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor | |
| EP4116298A4 (en) | Piperidinedione derivative | |
| EP3866765A4 (en) | Injectable long-acting naltrexone microparticle compositions | |
| EP4450502A4 (en) | Azaindole derivative inhibiting h-pgds | |
| EP4138783A4 (en) | Long-acting bupivacaine microsphere formulations | |
| EP4347973A4 (en) | Improved prop assemblies | |
| HK40115534A (en) | Long-acting glp-1 compound | |
| HK40094144A (en) | Long-acting formulations | |
| HK40099053A (en) | Long-acting dnase | |
| HK40101507A (en) | Borono-phenylalanine derivative | |
| HK40094126A (en) | 5-heteroaryl-1h-pyrazol-3-amine derivative | |
| HK40089693B (en) | Dimethylsulfoximine derivative | |
| HK40089693A (en) | Dimethylsulfoximine derivative | |
| HK40109784A (en) | Insulin derivative | |
| HK40102509A (en) | Glucagon like peptide compounds | |
| HK40119151A (en) | Dihydro-oxazol derivative compounds | |
| HK40070502B (en) | Insulin derivative | |
| AU2020900461A0 (en) | Centraliser | |
| HK40109423A (en) | New aryl-pyrido-pyrimidin-one derivatives | |
| HK40104845A (en) | Camptothecin derivatives | |
| HK40093036A (en) | New thiazolopyrimidinone derivatives | |
| HK40094396A (en) | New thienopyrimidinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230622 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20240723 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/10 20060101ALI20240717BHEP Ipc: A61P 3/06 20060101ALI20240717BHEP Ipc: A61P 3/04 20060101ALI20240717BHEP Ipc: A61P 1/16 20060101ALI20240717BHEP Ipc: C07K 1/04 20060101ALI20240717BHEP Ipc: A61K 38/26 20060101ALI20240717BHEP Ipc: C07K 14/605 20060101AFI20240717BHEP |